Clinical benefit from neoadjuvant chemotherapy in oestrogen receptor-positive invasive ductal and lobular carcinomas

Y. Delpech; C. Coutant; L. Hsu; E. Barranger; Takayuki Iwamoto; C. H. Barcenas; G. N. Hortobagyi; R. Rouzier; F. J. Esteva; L. Pusztai

doi:10.1038/bjc.2012.557

Clinical benefit from neoadjuvant chemotherapy in oestrogen receptor-positive invasive ductal and lobular carcinomas

Y. Delpech, C. Coutant, L. Hsu, E. Barranger, Takayuki Iwamoto, C. H. Barcenas, G. N. Hortobagyi, R. Rouzier, F. J. Esteva, L. Pusztai

Research output: Contribution to journal › Article

32 Citations (Scopus)

Abstract

Background:The aim of this study was to compare clinical and pathological outcomes after neoadjuvant chemotherapy between oestrogen receptor (ER)-positive invasive pure lobular carcinoma (ILC) and invasive ductal carcinoma (IDC).Methods:This analysis included 1895 patients (n=177 ILC; n=1718 IDC), with stage I-III breast cancer, who received neoadjuvant chemotherapy. Clinical and pathological response rates, the frequency of positive surgical margins and rate of breast-conserving surgery were compared.Results:There was a trend for fewer good clinical responses in ILC compared with IDC. Tumour downstaging was significantly less frequent in ILC. Positive or close surgical resection margins were more frequent in ILC, and breast-conserving surgery was less common (P

Original language	English
Pages (from-to)	285-291
Number of pages	7
Journal	British Journal of Cancer
Volume	108
Issue number	2
DOIs	https://doi.org/10.1038/bjc.2012.557
Publication status	Published - Feb 2013
Externally published	Yes

Fingerprint

Keywords

Breast cancer
Clinical response
Lobular carcinoma
Margins
Neoadjuvant chemotherapy
Pathological complete response

ASJC Scopus subject areas

Cancer Research
Oncology

Cite this

Delpech, Y., Coutant, C., Hsu, L., Barranger, E., Iwamoto, T., Barcenas, C. H., Hortobagyi, G. N., Rouzier, R., Esteva, F. J., & Pusztai, L. (2013). Clinical benefit from neoadjuvant chemotherapy in oestrogen receptor-positive invasive ductal and lobular carcinomas. British Journal of Cancer, 108(2), 285-291. https://doi.org/10.1038/bjc.2012.557

Clinical benefit from neoadjuvant chemotherapy in oestrogen receptor-positive invasive ductal and lobular carcinomas. / Delpech, Y.; Coutant, C.; Hsu, L.; Barranger, E.; Iwamoto, Takayuki; Barcenas, C. H.; Hortobagyi, G. N.; Rouzier, R.; Esteva, F. J.; Pusztai, L.

In: British Journal of Cancer, Vol. 108, No. 2, 02.2013, p. 285-291.

Research output: Contribution to journal › Article

@article{0f92c38d9a8b43c78ca26b2d55605069,

title = "Clinical benefit from neoadjuvant chemotherapy in oestrogen receptor-positive invasive ductal and lobular carcinomas",

abstract = "Background:The aim of this study was to compare clinical and pathological outcomes after neoadjuvant chemotherapy between oestrogen receptor (ER)-positive invasive pure lobular carcinoma (ILC) and invasive ductal carcinoma (IDC).Methods:This analysis included 1895 patients (n=177 ILC; n=1718 IDC), with stage I-III breast cancer, who received neoadjuvant chemotherapy. Clinical and pathological response rates, the frequency of positive surgical margins and rate of breast-conserving surgery were compared.Results:There was a trend for fewer good clinical responses in ILC compared with IDC. Tumour downstaging was significantly less frequent in ILC. Positive or close surgical resection margins were more frequent in ILC, and breast-conserving surgery was less common (P",

keywords = "Breast cancer, Clinical response, Lobular carcinoma, Margins, Neoadjuvant chemotherapy, Pathological complete response",

author = "Y. Delpech and C. Coutant and L. Hsu and E. Barranger and Takayuki Iwamoto and Barcenas, {C. H.} and Hortobagyi, {G. N.} and R. Rouzier and Esteva, {F. J.} and L. Pusztai",

year = "2013",

month = feb

doi = "10.1038/bjc.2012.557",

language = "English",

volume = "108",

pages = "285--291",

journal = "British Journal of Cancer",

issn = "0007-0920",

publisher = "Nature Publishing Group",

number = "2",

}

TY - JOUR

T1 - Clinical benefit from neoadjuvant chemotherapy in oestrogen receptor-positive invasive ductal and lobular carcinomas

AU - Delpech, Y.

AU - Coutant, C.

AU - Hsu, L.

AU - Barranger, E.

AU - Iwamoto, Takayuki

AU - Barcenas, C. H.

AU - Hortobagyi, G. N.

AU - Rouzier, R.

AU - Esteva, F. J.

AU - Pusztai, L.

PY - 2013/2

Y1 - 2013/2

N2 - Background:The aim of this study was to compare clinical and pathological outcomes after neoadjuvant chemotherapy between oestrogen receptor (ER)-positive invasive pure lobular carcinoma (ILC) and invasive ductal carcinoma (IDC).Methods:This analysis included 1895 patients (n=177 ILC; n=1718 IDC), with stage I-III breast cancer, who received neoadjuvant chemotherapy. Clinical and pathological response rates, the frequency of positive surgical margins and rate of breast-conserving surgery were compared.Results:There was a trend for fewer good clinical responses in ILC compared with IDC. Tumour downstaging was significantly less frequent in ILC. Positive or close surgical resection margins were more frequent in ILC, and breast-conserving surgery was less common (P

AB - Background:The aim of this study was to compare clinical and pathological outcomes after neoadjuvant chemotherapy between oestrogen receptor (ER)-positive invasive pure lobular carcinoma (ILC) and invasive ductal carcinoma (IDC).Methods:This analysis included 1895 patients (n=177 ILC; n=1718 IDC), with stage I-III breast cancer, who received neoadjuvant chemotherapy. Clinical and pathological response rates, the frequency of positive surgical margins and rate of breast-conserving surgery were compared.Results:There was a trend for fewer good clinical responses in ILC compared with IDC. Tumour downstaging was significantly less frequent in ILC. Positive or close surgical resection margins were more frequent in ILC, and breast-conserving surgery was less common (P

KW - Breast cancer

KW - Clinical response

KW - Lobular carcinoma

KW - Margins

KW - Neoadjuvant chemotherapy

KW - Pathological complete response

UR - http://www.scopus.com/inward/record.url?scp=84873567924&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873567924&partnerID=8YFLogxK

U2 - 10.1038/bjc.2012.557

DO - 10.1038/bjc.2012.557

M3 - Article

C2 - 23299541

AN - SCOPUS:84873567924

VL - 108

SP - 285

EP - 291

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 2

ER -

Access to Document

10.1038/bjc.2012.557